Biomethodes to present details of THR™, a breakthrough in protein stability engineering

Biomethodes announces to unveil the details of its technology THR™ for stabilising proteins at several international conferences, starting next week.

Biomethodes, a leader in protein engineering, is the inventor of Massive Mutagenesis®, the first technology enabling large and custom library generation, now a well validated technique.

The company has developed THR™, a breakthrough in protein stability engineering. THR™ relies on the first ever described system to directly select stable variants of a protein. THR™ is particularly useful to rapidly improving the stability of any protein, and especially enzymes and therapeutic proteins.

This highly innovative technology has already led to the quick identification of new variants of a therapeutic protein, interferon gamma, displaying an improved stability. Using THR™ these variants were isolated in only four months, and could not have been found using state-of-the-art technologies.

Details of THR™ will be presented at the following future events:

• Multistep Enzyme Catalysed Processes, April 18-21, 2006, Graz, Austria
• PEGS, the Protein Engineering Summit, April 24-28, 2006, Boston, MA, USA
• Industrial biotransformations, May 4-6, 2006, Barcelona, Spain
• ACHEMA 2006, May 15-19, 2006, Frankfurt, Germany

Biomethodes is now using THR™ extensively to generate a pipeline of proprietary, stable proteins. THR™ is also offered as a service to industrial partners.